The role of DPF2 stability in SMARCB1-deficient cancers
DPF2 稳定性在 SMARCB1 缺陷型癌症中的作用
基本信息
- 批准号:10751414
- 负责人:
- 金额:$ 4.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:ATAC-seqAcute Myelocytic LeukemiaAdenocarcinomaAffectAffinityApoptosisAutomobile DrivingBindingBiological AssayCancer cell lineCell Culture TechniquesCell LineCell ProliferationChemotherapy and/or radiationChromatinChromatin Remodeling FactorCo-ImmunoprecipitationsCombined Modality TherapyComplexDataEnhancersEpigenetic ProcessFlow CytometryFutureGene Expression RegulationGenesGenetic TranscriptionGlycerolGoalsHistonesHumanImmunoprecipitationIn VitroKnowledgeLeadMalignant Childhood NeoplasmMalignant NeoplasmsMass Spectrum AnalysisMeasuresMediatingMentorsMissense MutationModelingMolecularMutationNonsense MutationNormalcyNucleic Acid Regulatory SequencesNucleosomesOncogenicOperative Surgical ProceduresPatient-Focused OutcomesPatientsPediatric OncologyPhenotypePlayPositioning AttributePrognosisProteasome InhibitionProteinsReaderRecurrenceRegulator GenesRhabdoid TumorRoleSMARCB1 geneScientistSedimentation processStainsSurvival RateTestingTherapeuticToxic effectTrainingTranscriptional RegulationTumor Suppressor ProteinsUreaWestern BlottingWorkbeta-Galactosidasegenome-wideimprovedimproved outcomein vivoinsightloss of functionmutantmutation screeningnew therapeutic targetnoveloverexpressionposttranscriptionalrecruitsenescencesuccesstargeted treatmenttherapeutic targettranscriptome sequencingtreatment and outcometumor
项目摘要
PROJECT SUMMARY
Rhabdoid tumors are one of the most aggressive and lethal cancers in pediatric oncology with overall 5-year
survival rates of ~20-25%. Loss of SMARCB1 is the primary recurrent genetic alteration found in over 90% of
cases. Recent advances have implicated SMARCB1 loss in a number of other cancers broadly referred to as
SMARCB1-deficient cancers. SMARCB1 is a critical component of the BAF chromatin remodeling complex, a
complex which controls gene transcription by positioning nucleosomes at gene regulatory regions. Targeted
localization of the BAF complex to enhancers has largely been attributed to SMARCB1, yet no domain has been
identified on SMARCB1 that is able to recognize and bind specific histone marks. Instead SMARCB1 is only able
to nonspecifically bind to nucleosomes. This raises a key question: how does the BAF complex recognize
regulatory regions such as enhancers and bind. Recent work has shown that deletion of SMARCB1 depletes an
adjacent BAF subunit, DPF2, which is able to recognize and bind histone marks associated with enhancers. Re-
expression of SMARCB1 in a SMARCB1-deficient cell line leads to a robust accumulation of DPF2. The histone
reader protein, DPF2, has previously been implicated in the recruitment of the BAF complex to regulatory
regions. Through deep mutational scanning of SMARCB1, we have identified four missense mutations in
SMARCB1 that seem to mimic an oncogenic loss of function nonsense mutation. These residues are predicted
to directly interact with DPF2, which suggests SMARCB1 mediates its tumor suppressor role at least partially
through its interaction with DPF2. Moreover, we have identified a novel tumor suppressor role of DPF2 in the
context of constitutive overexpression in two SMARCB1-deficient cancers cell lines. For this reason, we
hypothesize that depletion of DPF2 is required in SMARCB1-deficient cancers. In Aim 1, I will test the hypothesis
that reduced DPF2 association with the BAF complex is driving this observed loss of function phenotype by
assessing the phenotypic, structural, and regulatory effects of each proposed SMARCB1 mutant. In Aim 2, I will
test the hypothesis that stabilization of DPF2 may be a promising therapeutic strategy to restore transcription
normalcy despite the loss of SMARCB1. In this aim I will characterize the phenotypic, structural, and regulatory
consequences of DPF2 overexpression in SMARCB1-deficent cell lines and determine if this is occurring through
either a BAF-dependent or BAF-independent mechanism. Together these aims will provide fundamental insight
into the mechanisms through which SMARCB1 exerts its tumor suppressor function, as well as expand our
understanding of DPF2 in SMARCB1-deficient cancers as a potential therapeutic target.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GARRETT COOPER其他文献
GARRETT COOPER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Computing analysis of leukemic stem cell dynamics in acute myelocytic leukemia
急性粒细胞白血病白血病干细胞动力学的计算分析
- 批准号:
19K08356 - 财政年份:2019
- 资助金额:
$ 4.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation of immunotoxins with super-targeting mAb in the acute myelocytic leukemia
在急性髓细胞白血病中使用超靶向单克隆抗体产生免疫毒素
- 批准号:
23501309 - 财政年份:2011
- 资助金额:
$ 4.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556971 - 财政年份:1980
- 资助金额:
$ 4.77万 - 项目类别:
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556968 - 财政年份:1980
- 资助金额:
$ 4.77万 - 项目类别:
ERADICATION OF ACUTE MYELOCYTIC LEUKEMIA CELLS BY MAB THERAPY
通过 MAB 疗法根除急性粒细胞白血病细胞
- 批准号:
3889304 - 财政年份:
- 资助金额:
$ 4.77万 - 项目类别:














{{item.name}}会员




